Showing 1801-1810 of 5643 results for "".
- Locus Biosciences Announces Collaboration with Viatris to Develop Antibacterial Therapies for Ophthalmic Infectionshttps://modernod.com/news/locus-biosciences-announces-collaboration-with-viatris-to-develop-antibacterial-therapies-for-ophthalmic-infections/2484292/Locus Biosciences announced a research collaboration agreement with Viatris to develop novel engineered bacteriophage therapies targeting ophthalmic bacterial infections. While financial terms of the deal were not disc
- Bausch + Lomb's Surgical Planning Software, Eyetelligence, Now Fully Commercially Available in UShttps://modernod.com/news/bausch-lombs-surgical-planning-software-eyetelligence-now-fully-commercially-available-in-us/2484204/Bausch + Lomb announced that its surgical planning software, Eyetelligence, is now available to all US ophthalmologists. Eyetelligence is designed to streamline a clinic’s operations and bring connectivity into the OR. According to B+L, the software helps surgeons make quick
- Hadley and Notal Vision Partner to Empower Patients With Vision Loss Through Education and Leading Technologyhttps://modernod.com/news/hadley-and-notal-vision-partner-to-empower-patients-with-vision-loss-through-education-and-leading-technology/2482860/Hadley and Notal Vision announced a strategic partnership to bridge the gap between early detection, treatment monitoring, and adaptive living for patients with age-related macular degeneration (AMD). The collaboration will connect users of Notal Vision’s ForeseeHome and SCANLY Ho
- Qlaris Bio Developing Fixed-Dose Combination Therapy for the Treatment of Glaucomahttps://modernod.com/news/qlaris-bio-developing-fixed-dose-combination-therapy-for-the-treatment-of-glaucoma/2482844/Qlaris Bio announced it is developing a novel preservative-free, fixed-dose combination therapy that combines the company’s lead program, QLS-111, and latanoprost. The fixed-dose combination (QLS-111-FDC) is being developed as a treatment for p
- CE-Mark Granted to deepeye Medical for AI Tool for Retinal Therapy Planninghttps://modernod.com/news/ce-mark-granted-to-deepeye-medical-for-ai-tool-for-retinal-therapy-planning/2482816/deepeye Medical has received CE Mark for its deepeye TPS¹ (Therapy Planning Support) platform. The Class IIa approval was made under the EU Medical Device Regulation (MDR 2017/745), following certification by the Notified Body
- Registration Now Open for Neuro-Optometric Rehabilitation Association (NORA) 2025 Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-nora-2025-conference/2482791/The Neuro-Optometric Rehabilitation Association, International (NORA), which advocates for advancing neurovisual rehabilitation, has opened registration for its 35th Annual Conference, taking place September 18–21, 2025, at the Hilton Denver City Center in Denver, Colorado. N
- Kiora Pharmaceuticals Presents In Data Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathyhttps://modernod.com/news/kiora-pharmaceuticals-presents-in-data-demonstrating-the-potential-of-kio-104-to-treat-proliferative-vitreoretinopathy/2482784/Kiora Pharmaceuticals announced the results from a preclinical study demonstrating KIO-104 significantly reduced scar formation in an established in vivo model of proliferative vitreoretinopathy (PVR). The presentation, titled, "KIO-104, a novel small molecule inhibitor o
- Medical Journals Cite “Harassment” After Increased Scrutiny from Justice Departmenthttps://modernod.com/news/medical-journals-cite-harassment-after-increased-scrutiny-from-justice-department/2482762/At least three major medical journals have reported receiving a letter from the U.S. Department of Justice (DOJ) that questioned their editorial practices and st
- Nordic Pharma Launches Authorized Generic of Maxitrolhttps://modernod.com/news/nordic-pharma-launches-authorized-generic-of-maxitrol/2482759/Nordic Pharma announced a partnership with Harrow to launch an authorized generic of Maxitrol (Neomycin and Polymyxin B Sulfates and Dexamethasone ophthalmic suspension), for the treatment and relief of bacterial eye infections. Maxitrol and generic equivalents had a
- Atsena Granted FDA Regenerative Medicine Advanced Therapy Designation for Gene Therapy to Treat X-Linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-granted-fda-regenerative-medicine-advanced-therapy-designation-gene-therapy-to-treat-x-linked-retinoschisis/2482737/Atsena Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s novel spreading capsid, to